Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
One-Compartment Model: IV Infusion01:09

One-Compartment Model: IV Infusion

Intravenous (IV) infusion is often utilized when continuous and controlled drug delivery is necessary, such as during surgery or in the treatment of chronic diseases. This method offers numerous advantages, including immediate drug action, precise control over dosage, and bypassing the first-pass metabolism.
The one-compartment model for IV infusion uses mathematical equations to describe the rate of change in drug quantity in the body. At steady-state or infusion equilibrium, the drug input...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Natural Quassinoid Brusatol Enhances Venetoclax Efficacy and Overcomes Resistance in Myeloid Leukemias.

Cancer science·2026
Same author

Cost-effectiveness of blinatumomab as post-remission therapy in adults with measurable residual disease-negative, Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia.

British journal of haematology·2026
Same author

Threshold for cytomegalovirus DNA PCR for preemptive treatment after allogeneic stem cell transplantation.

International journal of hematology·2026
Same author

<i>Pneumocystis jirovecii</i> infection in autologous hematopoietic stem cell transplantation.

Leukemia & lymphoma·2026
Same author

The combination of venetoclax with dimethyl fumarate synergistically induces apoptosis in AML cells by disrupting mitochondrial integrity through ROS accumulation.

Cell death & disease·2025
Same author

Significance of the tendency for relative bradycardia during induction therapy for acute myeloid leukemia.

International journal of hematology·2025

Related Experiment Video

Updated: Jun 28, 2026

Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.
12:17

Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.

Published on: March 17, 2008

[Infusion reactions].

Kazuya Sato1, Yutaka Kohgo

  • 1Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical College, Hokkaido, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 22, 2008
PubMed
Summary

Monoclonal antibody treatments are effective cancer therapies with fewer side effects. Close monitoring and prompt management of infusion reactions are crucial for patient safety during treatment.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Context:

  • Monoclonal antibodies represent a significant advancement in molecular targeted cancer therapy.
  • These therapies are increasingly vital due to their efficacy and improved side effect profiles compared to traditional treatments.

Purpose:

  • To highlight the nature, timing, and management of infusion reactions associated with monoclonal antibody therapy.
  • To emphasize the importance of patient monitoring and preparedness among healthcare professionals.

Summary:

  • Infusion reactions, resembling hypersensitivity, are acute adverse events common in monoclonal antibody treatment, typically occurring within the first two hours of the initial infusion.
  • While often mild-to-moderate and manageable with supportive care or temporary infusion interruption, severe or life-threatening reactions necessitate vigilant observation.

Related Experiment Videos

Last Updated: Jun 28, 2026

Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.
12:17

Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.

Published on: March 17, 2008

  • Effective management requires healthcare staff to be informed about reaction timing, prevention strategies, and prompt intervention protocols.

    • Impact:

    • Ensuring patient safety during monoclonal antibody infusions through informed monitoring and rapid response systems.
    • Improving patient and medical staff understanding of potential infusion reactions to optimize cancer treatment outcomes.
    • Establishing standardized protocols for managing infusion reactions can enhance the overall therapeutic experience and reduce adverse event severity.